David Sallman, MD

Articles by David Sallman, MD

David Sallman, MD, on Updates From the AMELI-01 Trial of UCART123v1.2 for AML

February 4th 2023

The assistant member of the department of malignant hematology at Moffitt Cancer Center discussed updated data on the allogeneic CAR T therapy, UNICART123v1.2.

David Sallman, MD, on Advantages of Allogeneic CAR T-Cell Therapy in AML

ByDavid Sallman, MD

December 15th 2022

The assistant member of the department of malignant hematology at Moffitt Cancer Center discussed unmet needs in acute myeloid leukemia and how UCART123v1.2 may address these.

David Sallman, MD

Articles by David Sallman, MD

David Sallman, MD, on Updates From the AMELI-01 Trial of UCART123v1.2 for AML

David Sallman, MD, on Advantages of Allogeneic CAR T-Cell Therapy in AML

Latest Updated Articles

Trending on CGTlive®

Patients Treated With AskBio’s Limb-Girdle Muscular Dystrophy Gene Therapy AB-1003 Free of Serious Adverse Events at Up to 52 Weeks

Patients Treated With Spur Therapeutics’ Gaucher Disease Gene Therapy FLT201 Maintain Clinical Benefit for Up to 2 Years

CGTLive®’s Weekly Rewind – October 17, 2025